Manabu Murakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manabu Murakami has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Torahiko Jinta
Department of Respiratory Medicine, Thoracic Center St. Luke's International Hospital Tokyo Japan
5 shared publicationsRyosuke Imai
Department of Respiratory Medicine, Thoracic Center St. Luke's International Hospital Tokyo Japan
4 shared publications- Atsushi Kitamura
St. Luke's International Hospital, Tokyo, Japan
3 shared publications - Kotaro Matoba
Graduate School of Medicine, Center for Cause of Death Investigation, Hokkaido University, Japan; Department of Forensic Medicine, Graduate School of Medicine, Hokkaido University, Japan
3 shared publications - Shosei Ro
Department of Respiratory Medicine, St. Luke's International Hospital, Tokyo, Japan
3 shared publications Tomohide Tamura
Department of Respiratory Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 15 September 2023
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 86 (11) , 1037-1038
The importance of early clinical exposure and interprofessional collaboration: Commonalities between Taiwan and Japan in the field of community medicine
An abstract is unavailable. This article is available as a PDF only.
- 15 September 2023
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 86 (11) , 1037-1038
Open AccessThe importance of early clinical exposure and interprofessional collaboration: Commonalities between Taiwan and Japan in the field of community medicine
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 16 August 2023
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 20, 1
Objective Evaluation of Oral and Pharyngeal Areas in Autopsy Cases of Obstructive Sleep Apnea Syndrome via Postmortem CT
Background: Obstructive sleep apnea syndrome (OSAS) can cause sudden death during sleep. Previous findings have suggested that OSAS development is related to maxillofacial morphology. Evaluation of facial morphology can determine the risk of developing the disease, and establishing an objective method to assess the underlying etiology of OSAS-related death would be advantageous. Objective: The objective of this study is to determine the key features of obstructive sleep apnea syndrome (OSAS) using postmortem oral and pharyngeal computed tomography (CT). Methods: We retrospectively assessed autopsy cases of patients with (n=25) and without (n=25) OSAS-related death. We used oral and pharyngeal CT images to compare the oral and pharyngeal cavity volume (OPCV), oral and pharyngeal soft tissue volume (OPSV), oral and pharyngeal air space volume (OPAV), and OPAV to OPCV ratio (%air). Receiver operating curve (ROC) analysis was used to determine the accuracy of OSAS prediction. We assessed participants with body mass index (BMI) values within the normal range. Results: Among the 50 subjects, we observed significant between-group differences in OPSV, OPAV, and % air, whereas there were significant betweengroup differences in OPSV and %air among 28 subjects with normal BMI values. Both comparisons suggested that OSAS-related death was associated with low %air and high OPSV values. Conclusion: The % air and OPSV are useful for assessing postmortem oropharyngeal CT images. OSAS-related sudden death is likely when %air and OPSV values are ≤20.1% and ≥127.2 ml, respectively. Among those with normal BMI values, % air and OPSV values of ≤22.8% and ≥111.5 ml, respectively, predict OSAS-related sudden death.
- 16 August 2023
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 20, 1
Open AccessObjective Evaluation of Oral and Pharyngeal Areas in Autopsy Cases of Obstructive Sleep Apnea Syndrome via Postmortem CT
Background: Obstructive sleep apnea syndrome (OSAS) can cause sudden death during sleep. Previous findings have suggested that OSAS development is related to maxillofacial morphology. Evaluation of facial morphology can determine the risk of developing the disease, and establishing an objective method to assess the underlying etiology of OSAS-related death would be advantageous. Objective: The objective of this study is to determine the key features of obstructive sleep apnea syndrome (OSAS) using postmortem oral and pharyngeal computed tomography (CT). Methods: We retrospectively assessed autopsy cases of patients with (n=25) and without (n=25) OSAS-related death. We used oral and pharyngeal CT images to compare the oral and pharyngeal cavity volume (OPCV), oral and pharyngeal soft tissue volume (OPSV), oral and pharyngeal air space volume (OPAV), and OPAV to OPCV ratio (%air). Receiver operating curve (ROC) analysis was used to determine the accuracy of OSAS prediction. We assessed participants with body mass index (BMI) values within the normal range. Results: Among the 50 subjects, we observed significant between-group differences in OPSV, OPAV, and % air, whereas there were significant betweengroup differences in OPSV and %air among 28 subjects with normal BMI values. Both comparisons suggested that OSAS-related death was associated with low %air and high OPSV values. Conclusion: The % air and OPSV are useful for assessing postmortem oropharyngeal CT images. OSAS-related sudden death is likely when %air and OPSV values are ≤20.1% and ≥127.2 ml, respectively. Among those with normal BMI values, % air and OPSV values of ≤22.8% and ≥111.5 ml, respectively, predict OSAS-related sudden death.
- Open Access
- 17 October 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (11) , e01050
A case of a thoracic mass negative on thoracentesis diagnosed by cryobiopsy from the visceral pleura
Thoracoscopy under local anaesthesia is recommended for malignant tumours with negative pleural effusion cytology. Cryobiopsy from the visceral pleura by thoracoscopy under local anaesthesia can provide more diagnostic options for patients with thoracentesis‐negative malignant effusions. Here we present the first case in which this technique was used. The patient had a pleural metastasis that could not be diagnosed even with rapid cytology of the parietal pleura biopsy. Indications, technical pitfalls, and safety tips are discussed.
- 17 October 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (11) , e01050
Open AccessA case of a thoracic mass negative on thoracentesis diagnosed by cryobiopsy from the visceral pleura
Thoracoscopy under local anaesthesia is recommended for malignant tumours with negative pleural effusion cytology. Cryobiopsy from the visceral pleura by thoracoscopy under local anaesthesia can provide more diagnostic options for patients with thoracentesis‐negative malignant effusions. Here we present the first case in which this technique was used. The patient had a pleural metastasis that could not be diagnosed even with rapid cytology of the parietal pleura biopsy. Indications, technical pitfalls, and safety tips are discussed.
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 772-776
Reproducibility of peripheral branches in virtual bronchoscopic navigation using VINCENT and LungPoint software for peripheral lung lesions
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 772-776
Reproducibility of peripheral branches in virtual bronchoscopic navigation using VINCENT and LungPoint software for peripheral lung lesions
- Open Access
- 22 October 2021
- Published by Scientific Scholar
- Vol. 34 (3) , 188
Enhancing students’ motivations through early exposure in actual settings is key
- 22 October 2021
- Published by Scientific Scholar
- Vol. 34 (3) , 188
Open AccessEnhancing students’ motivations through early exposure in actual settings is key
- Open Access
- 30 June 2021
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 16 (1) , 781
Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy
Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.
- 30 June 2021
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 16 (1) , 781
Open AccessIdentification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy
Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.
- Open Access
- 25 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00613
Unilateral pleural effusion with capillary haemangioma
Here, we report a case of haemangioma on middle mediastinum accompanied by unilateral pleural effusion, which was initially suspected to be lung cancer and pleurisy. During annual check‐up, chest radiography of a 30‐year‐old female showed homogeneous opacity in the left lower pulmonary field. Excision was performed, and the mass was pathologically diagnosed as benign mediastinal vascular tumour with exudative pleural effusion. To our knowledge, this presentation occurs in <0.5% of tumours of the mediastinum, and furthermore, the presence of pleural fluid is extremely rare, and the underlying mechanism is unknown. Although mediastinal haemangioma is hard to diagnose without surgery, we should include it in the differential diagnosis of a tumour with unilateral pleural effusion.
- 25 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00613
Open AccessUnilateral pleural effusion with capillary haemangioma
Here, we report a case of haemangioma on middle mediastinum accompanied by unilateral pleural effusion, which was initially suspected to be lung cancer and pleurisy. During annual check‐up, chest radiography of a 30‐year‐old female showed homogeneous opacity in the left lower pulmonary field. Excision was performed, and the mass was pathologically diagnosed as benign mediastinal vascular tumour with exudative pleural effusion. To our knowledge, this presentation occurs in <0.5% of tumours of the mediastinum, and furthermore, the presence of pleural fluid is extremely rare, and the underlying mechanism is unknown. Although mediastinal haemangioma is hard to diagnose without surgery, we should include it in the differential diagnosis of a tumour with unilateral pleural effusion.
- Open Access
- 4 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00596
High‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series
We report a case series of seven mechanically ventilated patients with acute respiratory distress syndrome (ARDS) caused by coronavirus disease (COVID‐19) who received early treatment with high‐dose, short‐term systemic corticosteroids to prevent cytokine overproduction. Of the seven patients, four were male and median age was 69 years. They were intubated within seven days after admission when their respiratory status rapidly worsened. At that time, we administered 1000 or 500 mg/day for three days of methylprednisolone intravenously, followed by 1 mg/kg and tapered off. The median duration for the total administration of corticosteroids was 13 days. This high‐dose, short‐term corticosteroid therapy enabled extubation of the patients within seven days. Many questions on the clinical management of COVID‐19 remain unanswered, and data on corticosteroid therapy as a choice of treatment are mixed. We present the clinical course of our cases, review the previous evidence, and discuss management.
- 4 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00596
Open AccessHigh‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series
We report a case series of seven mechanically ventilated patients with acute respiratory distress syndrome (ARDS) caused by coronavirus disease (COVID‐19) who received early treatment with high‐dose, short‐term systemic corticosteroids to prevent cytokine overproduction. Of the seven patients, four were male and median age was 69 years. They were intubated within seven days after admission when their respiratory status rapidly worsened. At that time, we administered 1000 or 500 mg/day for three days of methylprednisolone intravenously, followed by 1 mg/kg and tapered off. The median duration for the total administration of corticosteroids was 13 days. This high‐dose, short‐term corticosteroid therapy enabled extubation of the patients within seven days. Many questions on the clinical management of COVID‐19 remain unanswered, and data on corticosteroid therapy as a choice of treatment are mixed. We present the clinical course of our cases, review the previous evidence, and discuss management.
- Open Access
- 15 February 2020
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 59 (4) , 563-567
Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study
Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hypersensitivity pneumonitis in the third. A retrospective survey of patients treated with eribulin at our hospital identified no other cases of eribulin-induced lung injuries. Overall, drug-related lung injuries occurred in 2.8% of our eribulin-treated patients, which is similar to the rates reported for other anticancer drugs. The findings from these three cases provide guidance for the safe use of eribulin.
- 15 February 2020
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 59 (4) , 563-567
Open AccessEribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study
Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hypersensitivity pneumonitis in the third. A retrospective survey of patients treated with eribulin at our hospital identified no other cases of eribulin-induced lung injuries. Overall, drug-related lung injuries occurred in 2.8% of our eribulin-treated patients, which is similar to the rates reported for other anticancer drugs. The findings from these three cases provide guidance for the safe use of eribulin.
- 26 January 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 229 (2) , 232-238
Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol
- 26 January 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 229 (2) , 232-238
Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol